drugset / Trial / NCT03580239
Everolimus in Castrated Resistant Prostate Cancer(CRPC)Patients With PI3K-AKT-mTOR Signaling Pathway Deficiency
Phase 3
Unknown
120 enrolled
Tianjin Medical University Second Hospital
The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine · collabTianjin First Central Hospital · collabTianjin Medical University General Hospital · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
Investigators seek a new therapeutic strategy for castrated resistant prostate cancer(CRPC) patients with PI3K-AKT-mTOR signaling pathway deficiency by next generation sequencing(NGS).
Timeline
- Start
- 2019-01-01
- Primary completion
- 2023-01-31
- Completion
- 2023-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | 10 mg | Oral |